Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We evaluated retrospectively a cohort of patients with germline TP53 pathogenic variants treated for localized breast cancer between December 1999 and October 2017.
|
31748977 |
2020 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We found that 0.5% of patients (50 cases) carried a pathogenic TP53 germline mutation in this large series of 10,053 unselected breast cancer patients, and the prevalence of TP53 germline mutation was 3.8% in very early onset breast cancer (age ≤30 years) in this large cohort.
|
31119730 |
2020 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The Dilemma of TP53 Codon 72 Polymorphism (rs1042522) and Breast Cancer Risk: A Case-Control Study and Meta-Analysis in The Iranian Population.
|
31721533 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Staining of p53 and PARP1 in breast cancer TMAs and comparison with the TCGA database indicated a higher double-positive signal in basal-like breast cancer than in Luminal A or Luminal B subtypes.
|
31776133 |
2020 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Although many genes, such as p53 and Rb1, have been shown to be mutated, deregulation of the canonical Wnt/β-catenin signaling pathway is frequently observed in OS.
|
31595984 |
2020 |
Li-Fraumeni Syndrome
|
1.000 |
Biomarker
|
disease |
BEFREE |
Notably, no individuals with confirmed germline or likely germline TP53 PVs met classic Li-Fraumeni syndrome (LFS) criteria, only 41% met Chompret LFS criteria, and 59% met neither criteria, based upon provider-reported personal and family cancer history.
|
31490007 |
2020 |
Li-Fraumeni Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Recently, the functional MIR605 variant rs2043556 (A>G) has been identified as a novel LFS phenotype modifier in families with germline TP53 DNA binding variants.
|
31778928 |
2020 |
Li-Fraumeni Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder associated with TP53 germline mutations and an increased lifetime risk of multiple primary cancers (MPC).
|
31719099 |
2020 |
Li-Fraumeni Syndrome
|
1.000 |
Biomarker
|
disease |
BEFREE |
This enabled successful estimation of TP53 penetrance for three LFS cancer types: breast (BR), sarcoma (SA), and others (OT), from 186 pediatric sarcoma families collected at MD Anderson Cancer Center.
|
31719101 |
2020 |
Li-Fraumeni Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In this cohort of patients with LFS enriched in TP53 p.R337H pathogenic variant, the incidence of RIMs after treatment of localized breast cancer was lower than previous literature.
|
31748977 |
2020 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
This enabled successful estimation of TP53 penetrance for three LFS cancer types: breast (BR), sarcoma (SA), and others (OT), from 186 pediatric sarcoma families collected at MD Anderson Cancer Center.
|
31719101 |
2020 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Conclusion: This study sheds light on the tumor suppressor role of lncRNA PSTAR, a modulator of the p53 pathway, in HCC.
|
31148184 |
2020 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
|
31670863 |
2020 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Advanced-stage HCC (BCLC B/C) showed higher frequencies of splicing factor 3b subunit 1 (SF3B1) (P = 0.0003), TP53 (P = 0.0006), and RB Transcriptional Corepressor 1 mutations (P = 0.03).
|
31206197 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
|
31391192 |
2019 |
Malignant neoplasm of breast
|
1.000 |
PosttranslationalModification
|
disease |
BEFREE |
Pulldown assays, used to search for proteins capable to selectively bind tRF3E, have shown that this tRF specifically interacts with nucleolin (NCL), an RNA-binding protein overexpressed in BC and able to repress the translation of p53 mRNA.
|
31560576 |
2019 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In addition, WRAP53-a natural antisense transcript-regulates TP53 transcription and, as a protein, modulates the normal cell cycle, which results in breast cancer susceptibility.
|
31387111 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, a higher proportion of G:C>T:A mutations was observed in TP53 in PRECAMA cases compared with TCGA and METABRIC BC series (27% vs 14%).
|
30653559 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Moreover, <i>in vitro</i> experiments confirmed that mutant p53 could increase BC immunogenicity.
|
31275382 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We searched for germline mutations in the TP53 gene using targeted next-generation sequencing (NGS) in 78 BC patients younger than 45 years old (yo) who tested negative for BRCA1/2 mutations.
|
30709381 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We transfected p21 and p53 tumor suppressor plasmids, into different breast cancer cell lines using inorganic nanoparticles (NPs) of carbonate apatite to evaluate the effect of gene expression on reducing breast cancer cell growth.
|
30898703 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
|
30470976 |
2019 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Abnormal oncogenic signaling has important effects on the development of breast cancer, such as ERα/ ESR1 (estrogen receptor alpha), PTEN (gene of phosphate and tension homology deleted on chromsome ten), NFκB(nuclear factor κB), and tumor protein p53 (p53 / TP53).
|
31518875 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Although the relative frequencies of different immunohistochemical subtypes of BC may be similar between the East and West, the higher prevalence of luminal B subtypes with more frequent mutations in TP53 may be confounded by disparities in early detection.
|
31095268 |
2019 |